Covington, KY - Bexion Pharmaceuticals was awarded the “Medical Professional Award” at the American Cancer Society’s Annual Striders’ Ball held on November 5, 2016. This is the first time the honor has been bestowed on a [...]
Covington, KY - Bexion Pharmaceuticals was honored as a finalists for the “2016 Inspiration in Cancer Research Award” at the Cancer Support Community’s (CSC) annual Evening of Hope Gala, held on October 29, 2016. “The Bexion [...]
Bexion Pharmaceuticals Doses First Patient in Phase I Trial of BXQ-350 For Patients with Advanced Solid Tumors at the University of Cincinnati Cancer Institute
Covington, KY - Bexion Pharmaceuticals, LLC (“Bexion”) and the University of Cincinnati Cancer Institute (UCCI) announced today the dosing of the first patient in the Phase I trial of BXQ-350, a novel anti-cancer therapeutic agent. This [...]
Bexion Pharmaceuticals is developing innovative cures for cancer.
Unlike any other potential drug known in development, BXQ-350 has an entirely new and novel mechanism of action.
In July 2016 Bexion received a “Study May Proceed” letter from the FDA, allowing Bexion to initiate the first clincial trial using BXQ-350 to dose patients with cancer (solid tumors and glioblastoma).
Information about the Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors trial can be found at https://www.clinicaltrials.gov/show/NCT02859857